LIR Life Sciences Corp.
SKNY
CNSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.02M | -1.60M | -141.20K | -102.00K | -154.50K |
| Total Depreciation and Amortization | 900.00 | 1.00K | 1.00K | 800.00 | -- |
| Total Amortization of Deferred Charges | -239.50K | 241.60K | -- | -- | -- |
| Total Other Non-Cash Items | 979.50K | 500.00K | -100.00 | 100.00 | -- |
| Change in Net Operating Assets | -24.30K | -305.50K | 136.40K | 66.00K | 97.30K |
| Cash from Operations | -305.60K | -1.16M | -4.00K | -35.10K | -57.20K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 71.20K | 1.05M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | 0.00 | -76.40K | -- |
| Cash from Investing | 71.20K | 1.05M | 0.00 | -76.40K | -- |
| Total Debt Issued | 0.00 | 0.00 | 5.00K | 35.00K | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -257.50K |
| Issuance of Common Stock | 0.00 | 0.00 | 1.07M | -- | 71.80K |
| Repurchase of Common Stock | 0.00 | -- | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.40K | -- | -- | -- | -8.00K |
| Cash from Financing | -2.50K | 0.00 | 773.00K | 25.50K | -136.30K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -236.90K | -109.70K | 768.90K | -86.10K | -193.50K |